The bioavailability enhancement services market is projected to grow at an annualized rate of 11.12% during the period 2021-2035, claims Roots Analysis

The bioavailability enhancement process is known to be fraught with several challenges, including its time and cost intensive nature; given the expertise available with service providers to improve pharmacokinetic properties of novel molecules, developers are actively outsourcing their requirements

Roots Analysis has announced the addition of “Bioavailability Enhancement Technologies and Services Market (2nd Edition), 2022-2035” report to its list of offerings

Considering the existing drug solubility and biocompatibility-related concerns and their impact on drug safety and patient compliance, the demand for bioavailability enhancement solutions has gained significant traction from the medical community. Drug developers have demonstrated a preference to continue relying on bioavailability enhancement service and technology providers, in order to optimize drug development cost and research timelines. Furthermore, driven by the large number of BCS class II and IV therapies in the current pipeline and growing demand for effective therapeutics, the bioavailability enhancement services market is expected to grow at a steady pace in the foreseen future.


Key Market Insights

~115 players currently claim to be engaged in providing bioavailability enhancement services
The bioavailability enhancement services market landscape is primarily characterized by the presence of small, mid-sized and large firms, which collectively constitute over 75% of the total share. Further, 45% of the service providers are based in North America, followed those having headquarters in Europe and Asia.

More than 75 bioavailability enhancement technologies are presently available in the market
Most (55%) of these technologies support solubility enhancement, followed by those providing support for sustained release drug delivery (46%). Additionally, nearly 70% of the technologies provide bioavailability enhancement services for solids, followed by liquids and fine particles / powders.

Partnership activity in this field has increased at a CAGR of nearly 35%, between 2013 and 2022
Mergers and acquisitions (~40%) emerged as the most common type of partnership models adopted by stakeholders engaged in this industry. Nearly 55% of the total deals were established post-2018, with the maximum activity being reported in 2021.

>9,600 patents related to bioavailability enhancement have been filed / granted, during 2003-2022
Majority (~80%) of the patents were filed as applications, followed by granted patents (20%). It is important to highlight that, nearly 1,200 patents were filed / granted in the year 2021. Further, 36% of the total patents were filed in North America, indicating the extensive R&D activity in this region.

4,700+ clinical trials evaluating bioavailability of drug candidates have been registered worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 24%, during the period 2010-2022. Of the total, more than 85% of the studies have already been completed, followed by active trials that are actively recruiting patients (~10%).

Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by stakeholders
The framework highlights the implementation of several advanced as well as traditional bioavailability enhancement approaches and technologies at different stages of the drug development pathway. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating such technologies, based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders.

Shifting focus of drug developers towards development of lipophilic drug compounds is anticipated to drive the demand for bioavailability enhancement technologies and services in the next 13 years
The outsourced commercial demand for bioavailability enhancement is projected to increase at a CAGR of ~10 %. Further, the current clinical demand for solid dosage form captures around 30% of the total demand.

North America and Europe are anticipated to capture more than 65% of the market share, by 2035
Owing to the high prevalence of diseases, increasing investments in formulation development research, and growing initiatives for drug discovery and personalized medicine in Asia, the bioavailability enhancement services market in Asia is likely to grow at a relatively faster pace (13.54%) in the long term. Further, in 2035, bioavailability enhancement services for new chemical entities are expected to dominate the market, capturing around 85% of the market share.


To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/198/request-

Key Questions Answered
 Who are the key players engaged in the bioavailability enhancement technologies and services market?
 Which are the key geographies where bioavailability enhancement technology and service providers are located?
 What are the recent developments and expected trends in the bioavailability enhancement industry?
 Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?
 What is the evolving trend of publications focused on bioavailability enhancement technologies?
 Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?
 What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement services market?
 How is the current and future opportunity likely to be distributed across key market segment?

The financial opportunity within the bioavailability enhancement services market has been analyzed across the following segments:

 Drug Class
 New Drug Approvals
 Generics

 BCS Classification
 BCS II Drugs
 BCS IV Drugs

 Bioavailability Enhancement Approach
 Solid Dispersion
 Size Reduction
 Lipid-based

 Dosage Form
 Liquids
 Solids
 Semi-Solids
 Fine Particles / Powders

 Key Geographies
 North America
 Europe
 Asia
 Latin America
 Middle East and North Africa (MENA)
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), recent developments (including partnerships and collaborations) and an informed future outlook.
 Adare Pharma Solutions
 Ascendia Pharmaceuticals
 Catalent
 Lonza
 Lubrizol Life Science Health
 Pace Life Sciences
 Quotient Sciences
 WuXi STA (a subsidiary of WuXi AppTec)

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - Bioavailability Enhancement Technologies and Services | Market Size | 2035

The space of bioavailability enhancement technologies and services, driven by the increase in number of BCS II and BCS IV molecules in early phases of development, is likely to grow at CAGR of ~11%, till 2035

Ashneer Grover represented as the company’s managing director and co-founder up until February 28, 2022, when he was made to step down and give up his positions there. In 2018, he and Shashvat Nakrani co-founded the business.
Read more: https://combonews.online/the-i....nspiring-success-sto

 

combonews.online

The Inspiring Success Story Of Former BharatPe Co-Founder And MD Ashneer Grover 

Ashneer Grover was born in Delhi on June 14, 1982, and he is a native of Delhi. Ashneer comes from a well-off family with a good education.

How to Play Satta Matka in 2023 | Luck lottery-style
https://sattakingm.in/
https://sattakingg.in/

Satta King is a popular lottery-style gambling game that is played across India. It was first introduced in the 1950s as a way to entice people to play the lottery.
This game involves writing numbers between 0 and 9 on pieces of paper and putting them in a Matka, an earthern pot. Then, one of the players randomly chooses a number and announces it.

 

sattakingm.in

Satta king 2023 | Sattaking | Satta result | Satta king online | Satta king live | Satta king result

Get 2023 - Satta King, satta result, satta king up, sattaking, gali result, satta result up, black satta, satta king 786, satta gali, satta king gali, desawar result, faridabaad result, gaziabaad result king

The long-acting drug delivery technologies market is projected to grow at a CAGR of 13%, till 2035, claims Roots Analysis

In order to mitigate the complexities associated with achieving a long-acting profile, drug developers have been inclined towards the utilization of long-acting drug delivery technologies and outsourcing certain operations to service providers.London
Roots Analysis has announced the addition of “Long-Acting Drug Delivery Technologies and Services Market, 2023-2035” report to its list of offerings.

The conventional treatment options available for several diseases are known to be associated with several challenges, such as patient non-compliance, non-adherence to medication and multiple dosing regimen. In order to circumvent the abovementioned challenges, the demand for long-acting drugs is increasing. The development and manufacturing of these novel pharmacological modalities require advanced long-acting drug delivery technologies and dedicated expertise available with service providers. It is worth mentioning that 70% of the technologies are compatible with injectables (depot and long-acting injections)


Key Market Insights

Over 110 long-acting drug delivery technologies are available, globally
Majority (28%) of the technologies are based on long-acting implants / devices, followed by those based on micro-encapsulation (24%). In addition, close to 40% of the technologies that are compatible with injectables can extend the dosing regimen up to months.

Over 40 companies claim to offer long-acting drug delivery contract services
Presently, the market is dominated by the presence of small (2-50 employees) and mid-sized (51-200 employees) players, who represent 70% of the contemporary market landscape. Notably, around 35% of the total players engaged in this space offer their services at all scales of operation.

Partnership activity in this domain has increased at a CAGR of ~10%, between 2018 and 2021
Maximum number of partnerships were inked in 2021 and 2022, indicating a recent rise in partnership activity. Majority of the deals were acquisitions (15%), followed by product development and technology licensing agreements (14%, each).

More than 570 articles focused on long-acting drug delivery, have been published in reputed scientific journals, since 2017
Around 85% of the publications were focused on research related to long-acting drug delivery. This is indicative of the extensive research activity being carried out in this domain.

Over 1,200 patents have been filed / published related to long-acting drug delivery, since 2018
Over 45% of these were granted patents, while around 55% were patent applications. Further, majority of the patent assignees were industry players. However, it is worth mentioning that the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 10%), over the past few years.

More than 400 grants were awarded to support ongoing R&D activities in long-acting drug delivery, between 2018 and 2022
Collectively, the capital amount awarded to support R&D in this field was estimated to be worth USD 207.2 million. It is worth noting that 97 grants were awarded in 2021, alone. A significant proportion of grants identified in the report (23%) were awarded under the NIH department of internal medicine, followed by those awarded under the department of biomedical engineering (16%).

Increased access to advanced technologies is anticipated to drive growth in this market at a CAGR of 13%, till 2035
Long-acting drug delivery technologies developed for the delivery of small molecules are likely to capture the highest share (~82%) in the market; this trend is unlikely to change in the foreseen future.

Long-acting drug delivery services market is expected to grow at a CAGR of 11%, till 2035
Based on compatible dosage form, majority of the revenue share (50%) is likely to be associated with injectables. On the other hand, the services market for vaginal dosage forms is expected to grow at a faster pace (CAGR of 11.9%), during the forecasted period.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/long-acting-


Frequently Asked Questions
 What are the major factors driving the long-acting drug delivery technologies and services market?
 How many long-acting drug delivery technologies, compatible with long-acting injectables, are available in the market?
 How many long-acting drug delivery technologies demonstrate extended dosage regimen of at least a year?
 How many long-acting drug delivery technologies demonstrate extended dosage regimen of at least a year?
 How many contract service providers possess technology transfer capabilities related to long-acting drug delivery?
 What are the partnership and collaboration trends in the long-acting drug delivery domain?
 What is the current patent landscape of long-acting drug delivery market?
 Which segment, in terms of strategy, accounts for the largest share in the global long-acting drug delivery technologies market?
 Which geography is expected to witness the highest growth rate in the long-acting drug delivery services market?

The financial opportunity within the gene therapy market has been analyzed across the following segments:
 Principle
 Manipulation of drug release from delivery systems
 Manipulation of in vivo clearance

 Strategy
 Chemical Modification
 Micro-encapsulation
 Long-Acting Hydrogels
 Long-Acting Implants
 Long-Acting Microneedles
 Multivesicular Liposomes
 Nanocrystal Suspensions
 Protein Fusion

 Compatible Dosage Form
 Injectables
 Implantables
 Oral Dosage Forms
 Topical / Transdermal Dosage Forms
 Vaginal Dosage Forms
 Other Dosage Forms

 Type of Molecules Delivered
 Small Molecules
 Biologics
 Other Molecules

 Type of Material Used
 Polymer based
 Non-polymer based

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Middle East and North Africa
The research includes brief profiles of key players (listed below) engaged in offering technologies and services related to long-acting drug delivery; each profile features a brief overview of the company, details related to its technology and service portfolio, recent developments and an informed future outlook.
 Adare Pharma Solutions
 AMW
 Bostal Drug Delivery
 Creative Biolabs
 ForDoz Pharma
 Innocore Pharmaceuticals
 Integral BioSystems
 LATITUDE Pharmaceuticals
 Navin Saxena Research and Technology Centre (NSRT)
 Samyang Biopharm

For additional details, please visit https://www.rootsanalysis.com/....reports/long-acting-

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - Long-Acting Drug Delivery Market | Industry Analysis | Market Size | 2035

Long-acting drug delivery technologies, driven by presence of nearly 100 companies, is anticipated to grow at 13% CAGR

Liposome – A Trending Novel Drug Delivery System

In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material.

Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids. Owing to their ability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules, liposomes are extensively used as efficient delivery systems for antigens or drugs. They can protect a drug from being detected by the body’s immune system by imitating biological membranes and providing the drug more time to reach its target destination.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/liposome-man

Liposomes offer great therapeutic efficacy and safety. They have several applications in the biomedical field such as delivering drug to the desired site while minimizing drug exposure to normal tissues, increased delivery of potential medications to the cytosol, stabilizing therapeutic compounds, and removing barriers to cellular and tissue absorption.

In addition to the applications, liposomes are gaining popularity across various other fields, including drug delivery, agriculture, cosmetics, and food industry. Due to multiple advantages across diverse application areas, including enhanced biocompatibility, high biodegradability, low toxicity, weak immunogenicity, increased drug solubility, controlled distribution, ability to make surface modifications for targeted, extended, and sustained release, liposomes have been recognized as the most effective delivery system. Currently, there are several liposomal formulations clinically approved for the treatment of various diseases, including cancer, fungal and viral infections, and many are currently in advanced stages of clinical studies. Over the years, several companies involved in the development of liposomes have made significant efforts in conducting clinical trials for evaluating the efficacy of liposome-based therapeutics, for the treatment of various oncological disorders.

Owing to various advantages offered by liposomes, advanced liposome technology is being developed to fully substructure the therapeutic applications of liposomes and extensive research is being conducted to develop methods for liposomal formulation with high level of purity and sensitivity. Further, it is extremely desirable to develop novel manufacturing methods that allow for simple encapsulation of both hydrophobic and hydrophilic molecules without the need of organic solvents, specialized equipment, or complex infrastructures. Additionally, given that liposomes have demonstrated some clinical promise as drug delivery systems, future efforts should focus on enhancing the commercial availability and accessibility of liposome products across the globe, particularly in low- and middle-income countries. applications of liposomes in drug delivery (24%), and protein and peptide delivery (9%), which is indicative of the extensive research activities and clinical trials being conducted to evaluate the therapeutic potential of liposomes.


Despite several advancements, there are various challenges in development of liposomes, for which stakeholders are leveraging the expertise of various contract service providers offering development and manufacturing services. These service providers are actively upgrading their capabilities and infrastructure to accommodate the demand for these vesicles. Driven by the growing research efforts, development of advanced methods for preparation and characterization of liposomes, and efforts of various stakeholders, this segment of industry is likely to witness noteworthy growth in the foreseen future.

For additional details, please visit
https://www.rootsanalysis.com/....reports/liposome-man

You may also be interested in the following titles:

1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035
2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - Liposome Development and Liposome Manufacturing | Industry Analysis | Market Size | 2035

Liposome development and liposome manufacturing market, driven by over 70+ players providing services, is expected to grow rapidly in the coming decade

What are the fine capabilities of Agra Etawah Toll Road Project

Modern Road Makers is a private company incorporated on 15 March, 1994. It is classified as a private limited company and is located in Mumbai City, Maharashtra. Its authorized share capital is INR 31.10 cr and the total paid-up capital is INR 31.09 cr. Modern Road Makers operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2021. Its EBITDA has decreased by -30.23 % over the previous year. At the same time, its book networth has increased by 6.33 %.

The Agra Etawah Toll Road Project consists of the stretch of NH 2 between kilometers 199.66 and 323.525.

AETPL has been granted permission to feature six lanes to a 124. Fifty two km stretch of Uttar Pradesh's NH 2 on a BOT or DBFOT basis.

A list of the task's capabilities is provided beneath.

six-lane road measuring 124.52 kilometers in length.
84.725 kilometers make up the 750 lane-kilometer Administration road.
Slip road with a length of 30.282 km and three significant additions.
30 minor augmentations.
In the skies, seven.
Turbulence forces seven rail tracks to pass past 3.08 km of obstacles.
The lamps illuminate the 44.68 kilometers of the route.
Located in 164 underpasses, a confluence of 214 vehicular underpasses, 10 for light traffic, and 6 for pedestrians.
Four trucks stop 22 straight lanes of traffic.
Two toll-cost courts are necessary. FASTag
Cost of the project is Rs. 3,244 Cr.
The concession is valid for 24 years.

In This Highway Trip (Agra Etawah Toll Road Project) you will come across different scenic spots on your way to the destination. Various restaurants offer delicious food. while in agra you can witness the uttar pradesh culture and enjoy food form uttar pradesh dhabas. It's one of the most comfortable and smooth driving highways. You will be in a different world and be in awe of the beauty of the road. It is a well-planned road with six-lane concrete, which is India’s first. You can take short breaks on the trip to admire the scenic beauty. On both sides of the road, you will find Dhaba and Hotels. While traveling through this road, you can also make a pit-stop at Bharatpur National Park, the fourth famous vacationer site and Three globally renowned traveler destinations—the Taj Mahal, Fatehpur Sikri, and Red Post—have established Agra as a well-known vacation spot on the tour industry's map.. If you look at the India road trip route map, this is the most scenic highway you can find.

Satta King 786 | Selects the Correct Number
https://sattakingm.in/
https://sattakingg.in/

Satta King 786 is a lottery-based game that can be played online. It is an exciting game that requires dedication, affection, and trust.
In the game, a Satta Matka is responsible for helping players make their bets. He collects money and numbers from players in his area, and sends them to the company.

 

sattakingm.in

Satta king 2023 | Sattaking | Satta result | Satta king online | Satta king live | Satta king result

Get 2023 - Satta King, satta result, satta king up, sattaking, gali result, satta result up, black satta, satta king 786, satta gali, satta king gali, desawar result, faridabaad result, gaziabaad result king

The Satta King is a deadly bowling league paddle. That is what it was designed for. It is a full sized paddle that can do some serious damage to any novice players who don't have the slightest idea on how to handle or improve their skills on bowling. That is exactly the reason why many people love to
https://sattakingm.in/
#satta, #satta_king, #sattaking, #ajmerking, #sattakingfast, #playbazaar, #blacksattaking, #blacksatta , # shalimargame, # sattaking, #delhisattabajar, #दिल्लीदिसावर